Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
MRTX Mirati Therapeutics $59.65 -1.5 (-2.45%) 16:51 08/01/18 08/01 16:51 08/01/18 16:51 Earnings	Mirati Therapeutics reports Q2 EPS (94c), consensus (78c) » Reports Q2 revenue $0.00,… Reports Q2 revenue $0.00, consensus $40K. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
MRTX Mirati Therapeutics $50.95 0.65 (1.29%) 07:24 07/20/18 07/20 07:24 07/20/18 07:24 Recommendations	Mirati Therapeutics analyst commentary at H.C. Wainwright » Mirati Therapeutics price… Mirati Therapeutics price target raised to $63 from $42 at H.C. Wainwright. H.C. Wainwright analyst Edward White raised his price target for Mirati Therapeutics to $63 to reflect a higher probability of success for sitravatinib. The analyst now applies a 45% probability of success for sitravatinib monotherapy and projects revenues of $407M, $448M and $179M for sitravatinib in combination with checkpoint therapy, sitravatinib as a single agent and mocetinostat, respectively, in 2027. He keeps a Buy rating on Mirati Therapeutics. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
MRTX Mirati Therapeutics $52.45 1.05 (2.04%) 08:08 07/09/18 07/09 08:08 07/09/18 08:08 Recommendations	Mirati Therapeutics analyst commentary at Oppenheimer » Mirati Therapeutics price… Mirati Therapeutics price target raised to $62 from $35 at Oppenheimer. Oppenheimer analyst Leah Rush Cann raised her price target for Mirati Therapeutics to $62 from $35 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
MRTX Mirati Therapeutics $50.05 2.2 (4.60%) 07:37 07/05/18 07/05 07:37 07/05/18 07:37 Recommendations	Mirati Therapeutics analyst commentary at Citi » Mirati Therapeutics price… Mirati Therapeutics price target raised to $64 from $37 at Citi. Citi analyst Yigal Nochomovitz raised his price target for Mirati Therapeutics to $64 from $37 to reflect increased conviction on sitravatinib plus nivolumab in IO refractory non-small-cell lung cancer patients. The analyst updated his model to reflect the positive interim Phase 2 data reported in April and increased his peak share estimates for sitravatinib in IO refractory NSCLC patients to 24% from 12%. Further, Nochomovitz's sensitivity analysis for preclinical KRAS G12C inhibitor, MRTX849, points to "significant upside." While still preclinical, MRTX849 has garnered "substantial interested" from pharma and investors given the significant untapped market opportunity and the apparent superior preclinical profile versus competitor drugs, the analyst told investors in a research note dated Tuesday. He keeps a Buy rating on Mirati Therapeutics. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
DCPH Deciphera $41.02 2.34 (6.05%) , LOXO Loxo Oncology $180.15 1.96 (1.10%) … 07:26 07/05/18 07/05 07:26 07/05/18 07:26 Initiation	Deciphera, Loxo Oncology, Blueprint Medicines, Mirati Therapeutics initiated at SunTrust » Deciphera initiated with… Deciphera initiated with a Buy at SunTrust. SunTrust analyst Peter Lawson initiated Deciphera (DCPH) with a Buy rating and a price target of $60, citing the company's differentiated position of developing kinase inhibitors that can hit multiple mutations, potentially better controlling cancer. Given its wholly owned pipeline of 3 clinical drugs, the lead of which is targeting Gastrointestinal stromal tumor in two phase 3 trials by the second half of this year, the analyst recommends that investors acquire shares ahead of those readouts. Lawson further states that other kinase targeting peer companies such as Loxo Oncology (LOXO), Blueprint Medicines (BPMC), and Mirati Therapeutics (MRTX) also point to significant upside amid clinical validation progress. DCPH Deciphera $41.02 2.34 (6.05%) LOXO Loxo Oncology $180.15 1.96 (1.10%) BPMC Blueprint Medicines $65.45 0.7 (1.08%) MRTX Mirati Therapeutics $50.05 2.2 (4.60%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

MRTX Mirati Therapeutics $48.75 1.55 (3.28%) 04:55 06/29/18 06/29 04:55 06/29/18 04:55 Conference/Events	Mirati Therapeutics management to meet with Oppenheimer » Meeting to be held on the… Meeting to be held on the West Coast June 28-29 hosted by Oppenheimer. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	29 Jun
MRTX Mirati Therapeutics $47.20 -2.85 (-5.69%) 04:55 06/28/18 06/28 04:55 06/28/18 04:55 Conference/Events	Mirati Therapeutics management to meet with Oppenheimer » Meeting to be held on the… Meeting to be held on the West Coast June 28-29 hosted by Oppenheimer. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Jun 29 Jun
MRTX Mirati Therapeutics $49.20 -2.1 (-4.09%) 16:35 06/25/18 06/25 16:35 06/25/18 16:35 Hot Stocks	Mirati Therapeutics added to Russell 2000 Index » Mirati Therapeutics… Mirati Therapeutics announced that it has been added to the Russell 2000 Index, effective as of the open of the market on Monday, June 25, 2018, following Russell's annual reconstitution of its comprehensive set of U.S. and global equity indexes. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity market. The index is a subset of the Russell 3000 Index and represents approximately 10% of the total market capitalization of that index. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Jun 29 Jun
MRTX Mirati Therapeutics $51.45 0.95 (1.88%) 08:34 06/21/18 06/21 08:34 06/21/18 08:34 Conference/Events	Mirati Therapeutics management to meet with Oppenheimer » Meeting to be held on the… Meeting to be held on the West Coast June 28-29 hosted by Oppenheimer. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Jun 29 Jun
MRTX Mirati Therapeutics $49.15 0.3 (0.61%) 08:00 06/19/18 06/19 08:00 06/19/18 08:00 Recommendations	Mirati Therapeutics analyst commentary at SunTrust » Mirati Therapeutics price… Mirati Therapeutics price target raised to $60 from $40 at SunTrust. SunTrust analyst Peter Lawson raised his price target on Mirati Therapeutics to $60 and kept his Buy rating. The analyst cites the findings from his recent investor meetings with the management highlighting the "solid positioning and differentiated approach with sitra in immuno-oncology combination" as well as a solid set of catalysts expected in the second half. Lawson adds that he is increasingly confident about Mirati in IO relapsed and refractory non-small cell lung cancer, raising his estimated penetration rate to 30% from 20% while also boosting the likelihood of approval to 40% from 33%. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Jun 29 Jun

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial